Pharmacogenetic characteristics of the eosinophilia-myalgia syndrome

David A. Flockhart, Daniel J. Clauw, Elaine Buchert Sale, Jan Hewett, Raymond L. Woosley

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

This study tested the hypothesis that patterns of xenobiotic metabolism in patients with eosinophilia-myalgia syndrome (EMS) differed from healthy control subjects. We determined the genotypes of 27 EMS patients with EMS and 114 control subjects for the cytochrome P450 CYP2D6 polymorphism. The metabolic phenotypes of patients with EMS for S-mephenytoin hydroxylation (n = 17) and dapsone acetylation (n = 19) were determined and compared with 29 healthy control subjects. The incidence of the CYP2D6 poor metabolizer genotype (mutant/mutant) was 0.185 in patients with EMS and 0.061 in control subjects (Mantel-Haenszel, χ2 = 7.213, p = 0.007). The mephenytoin S/R ratios were 0.39 ± 0.23 in patients with EMS versus 0.18 ± 0.13 in control subjects (p ≤ 0.005). There was no difference in dapsone acetylation between the two groups. A pattern of xenobiotic metabolism may play a role in the pathogenesis of EMS, but the precise role that it plays remains unclear.

Original languageEnglish (US)
Pages (from-to)398-405
Number of pages8
JournalClinical Pharmacology and Therapeutics
Volume56
Issue number4
StatePublished - 1994
Externally publishedYes

Fingerprint

Eosinophilia-Myalgia Syndrome
Pharmacogenetics
Mephenytoin
Dapsone
Cytochrome P-450 CYP2D6
Xenobiotics
Acetylation
Healthy Volunteers
Genotype
Hydroxylation
Cytochrome P-450 Enzyme System
Phenotype
Incidence

ASJC Scopus subject areas

  • Pharmacology

Cite this

Flockhart, D. A., Clauw, D. J., Sale, E. B., Hewett, J., & Woosley, R. L. (1994). Pharmacogenetic characteristics of the eosinophilia-myalgia syndrome. Clinical Pharmacology and Therapeutics, 56(4), 398-405.

Pharmacogenetic characteristics of the eosinophilia-myalgia syndrome. / Flockhart, David A.; Clauw, Daniel J.; Sale, Elaine Buchert; Hewett, Jan; Woosley, Raymond L.

In: Clinical Pharmacology and Therapeutics, Vol. 56, No. 4, 1994, p. 398-405.

Research output: Contribution to journalArticle

Flockhart, DA, Clauw, DJ, Sale, EB, Hewett, J & Woosley, RL 1994, 'Pharmacogenetic characteristics of the eosinophilia-myalgia syndrome', Clinical Pharmacology and Therapeutics, vol. 56, no. 4, pp. 398-405.
Flockhart DA, Clauw DJ, Sale EB, Hewett J, Woosley RL. Pharmacogenetic characteristics of the eosinophilia-myalgia syndrome. Clinical Pharmacology and Therapeutics. 1994;56(4):398-405.
Flockhart, David A. ; Clauw, Daniel J. ; Sale, Elaine Buchert ; Hewett, Jan ; Woosley, Raymond L. / Pharmacogenetic characteristics of the eosinophilia-myalgia syndrome. In: Clinical Pharmacology and Therapeutics. 1994 ; Vol. 56, No. 4. pp. 398-405.
@article{da33776a9f544b839fdbfe09e396b276,
title = "Pharmacogenetic characteristics of the eosinophilia-myalgia syndrome",
abstract = "This study tested the hypothesis that patterns of xenobiotic metabolism in patients with eosinophilia-myalgia syndrome (EMS) differed from healthy control subjects. We determined the genotypes of 27 EMS patients with EMS and 114 control subjects for the cytochrome P450 CYP2D6 polymorphism. The metabolic phenotypes of patients with EMS for S-mephenytoin hydroxylation (n = 17) and dapsone acetylation (n = 19) were determined and compared with 29 healthy control subjects. The incidence of the CYP2D6 poor metabolizer genotype (mutant/mutant) was 0.185 in patients with EMS and 0.061 in control subjects (Mantel-Haenszel, χ2 = 7.213, p = 0.007). The mephenytoin S/R ratios were 0.39 ± 0.23 in patients with EMS versus 0.18 ± 0.13 in control subjects (p ≤ 0.005). There was no difference in dapsone acetylation between the two groups. A pattern of xenobiotic metabolism may play a role in the pathogenesis of EMS, but the precise role that it plays remains unclear.",
author = "Flockhart, {David A.} and Clauw, {Daniel J.} and Sale, {Elaine Buchert} and Jan Hewett and Woosley, {Raymond L.}",
year = "1994",
language = "English (US)",
volume = "56",
pages = "398--405",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Pharmacogenetic characteristics of the eosinophilia-myalgia syndrome

AU - Flockhart, David A.

AU - Clauw, Daniel J.

AU - Sale, Elaine Buchert

AU - Hewett, Jan

AU - Woosley, Raymond L.

PY - 1994

Y1 - 1994

N2 - This study tested the hypothesis that patterns of xenobiotic metabolism in patients with eosinophilia-myalgia syndrome (EMS) differed from healthy control subjects. We determined the genotypes of 27 EMS patients with EMS and 114 control subjects for the cytochrome P450 CYP2D6 polymorphism. The metabolic phenotypes of patients with EMS for S-mephenytoin hydroxylation (n = 17) and dapsone acetylation (n = 19) were determined and compared with 29 healthy control subjects. The incidence of the CYP2D6 poor metabolizer genotype (mutant/mutant) was 0.185 in patients with EMS and 0.061 in control subjects (Mantel-Haenszel, χ2 = 7.213, p = 0.007). The mephenytoin S/R ratios were 0.39 ± 0.23 in patients with EMS versus 0.18 ± 0.13 in control subjects (p ≤ 0.005). There was no difference in dapsone acetylation between the two groups. A pattern of xenobiotic metabolism may play a role in the pathogenesis of EMS, but the precise role that it plays remains unclear.

AB - This study tested the hypothesis that patterns of xenobiotic metabolism in patients with eosinophilia-myalgia syndrome (EMS) differed from healthy control subjects. We determined the genotypes of 27 EMS patients with EMS and 114 control subjects for the cytochrome P450 CYP2D6 polymorphism. The metabolic phenotypes of patients with EMS for S-mephenytoin hydroxylation (n = 17) and dapsone acetylation (n = 19) were determined and compared with 29 healthy control subjects. The incidence of the CYP2D6 poor metabolizer genotype (mutant/mutant) was 0.185 in patients with EMS and 0.061 in control subjects (Mantel-Haenszel, χ2 = 7.213, p = 0.007). The mephenytoin S/R ratios were 0.39 ± 0.23 in patients with EMS versus 0.18 ± 0.13 in control subjects (p ≤ 0.005). There was no difference in dapsone acetylation between the two groups. A pattern of xenobiotic metabolism may play a role in the pathogenesis of EMS, but the precise role that it plays remains unclear.

UR - http://www.scopus.com/inward/record.url?scp=0028091801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028091801&partnerID=8YFLogxK

M3 - Article

C2 - 7955801

AN - SCOPUS:0028091801

VL - 56

SP - 398

EP - 405

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 4

ER -